VERTEX PHARMACEUTICALS INC / MA Insider Trading for February 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for February 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 91.05 | 2,155 | 196,213 | 17,242 | |
| Feb 28 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 170.00 | 2,155 | 366,350 | 46,662 | 48.8 K to 46.7 K (-4.41 %) |
| Feb 28 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 91.05 | 2,155 | 196,213 | 48,817 | 46.7 K to 48.8 K (+4.62 %) |
| Feb 28 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 18,639 | |
| Feb 28 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 169.00 | 6,459 | 1,091,571 | 46,752 | 53.2 K to 46.8 K (-12.14 %) |
| Feb 28 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 86.52 | 1,554 | 134,452 | 53,211 | 51.7 K to 53.2 K (+3.01 %) |
| Feb 21 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 158.49 | 3,437 | 544,730 | 19,525 | 23 K to 19.5 K (-14.97 %) |
| Feb 15 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 152.26 | 2,022 | 307,870 | 51,657 | 53.7 K to 51.7 K (-3.77 %) |
| Feb 15 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 151.40 | 2,022 | 306,131 | 53,679 | 55.7 K to 53.7 K (-3.63 %) |
| Feb 14 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 153.92 | 300 | 46,176 | 46,662 | 47 K to 46.7 K (-0.64 %) |
| Feb 14 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 153.25 | 1,400 | 214,550 | 46,962 | 48.4 K to 47 K (-2.89 %) |
| Feb 14 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 152.26 | 1,100 | 167,486 | 48,362 | 49.5 K to 48.4 K (-2.22 %) |
| Feb 14 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 151.22 | 7,296 | 1,103,301 | 49,462 | 56.8 K to 49.5 K (-12.85 %) |
| Feb 14 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 150.44 | 3,200 | 481,408 | 56,758 | 60 K to 56.8 K (-5.34 %) |
| Feb 14 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 149.22 | 4,500 | 671,490 | 59,958 | 64.5 K to 60 K (-6.98 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | A | 155.57 | 9,783 | 1,521,941 | 9,783 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Grant | A | 0.00 | 4,219 | 0 | 27,175 | 23 K to 27.2 K (+18.38 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Grant | A | 0.00 | 6,322 | 0 | 22,956 | 16.6 K to 23 K (+38.01 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Option Exercise | A | 155.57 | 19,566 | 3,043,883 | 19,566 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Grant | A | 0.00 | 8,437 | 0 | 64,495 | 56.1 K to 64.5 K (+15.05 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Grant | A | 0.00 | 15,170 | 0 | 56,058 | 40.9 K to 56.1 K (+37.10 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Graney Thomas | Chief Financial Off ... | Option Exercise | A | 155.57 | 10,436 | 1,623,529 | 10,436 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Graney Thomas | Chief Financial Off ... | Grant | A | 0.00 | 4,500 | 0 | 13,289 | 8.8 K to 13.3 K (+51.20 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | A | 155.57 | 19,566 | 3,043,883 | 19,566 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Grant | A | 0.00 | 8,437 | 0 | 52,134 | 43.7 K to 52.1 K (+19.31 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Grant | A | 0.00 | 18,204 | 0 | 43,697 | 25.5 K to 43.7 K (+71.41 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | A | 155.57 | 23,479 | 3,652,628 | 23,479 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Grant | A | 0.00 | 10,125 | 0 | 64,458 | 54.3 K to 64.5 K (+18.64 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Grant | A | 0.00 | 15,170 | 0 | 54,333 | 39.2 K to 54.3 K (+38.74 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | A | 155.57 | 73,046 | 11,363,766 | 73,046 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Grant | A | 0.00 | 31,498 | 0 | 214,563 | 183.1 K to 214.6 K (+17.21 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Grant | A | 0.00 | 50,568 | 0 | 183,065 | 132.5 K to 183.1 K (+38.17 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | A | 155.57 | 19,566 | 3,043,883 | 19,566 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 8,437 | 0 | 76,402 | 68 K to 76.4 K (+12.41 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 18,204 | 0 | 67,965 | 49.8 K to 68 K (+36.58 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | A | 155.57 | 19,566 | 3,043,883 | 19,566 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Grant | A | 0.00 | 8,437 | 0 | 62,525 | 54.1 K to 62.5 K (+15.60 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Grant | A | 0.00 | 12,136 | 0 | 54,088 | 42 K to 54.1 K (+28.93 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | A | 155.57 | 23,479 | 3,652,628 | 23,479 | |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Grant | A | 0.00 | 10,125 | 0 | 74,785 | 64.7 K to 74.8 K (+15.66 %) |
| Feb 08 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Grant | A | 0.00 | 12,136 | 0 | 64,660 | 52.5 K to 64.7 K (+23.11 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 77.31 | 2,578 | 199,305 | 0 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 86.52 | 1,942 | 168,022 | 23,299 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 164.93 | 2,242 | 369,773 | 39,163 | 41.4 K to 39.2 K (-5.41 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 163.79 | 600 | 98,274 | 41,405 | 42 K to 41.4 K (-1.43 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 161.93 | 300 | 48,579 | 42,005 | 42.3 K to 42 K (-0.71 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 160.97 | 300 | 48,291 | 42,305 | 42.6 K to 42.3 K (-0.70 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 159.93 | 700 | 111,951 | 42,605 | 43.3 K to 42.6 K (-1.62 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 158.55 | 378 | 59,932 | 43,305 | 43.7 K to 43.3 K (-0.87 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 77.31 | 2,578 | 199,305 | 43,683 | 41.1 K to 43.7 K (+6.27 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 86.52 | 1,942 | 168,022 | 41,105 | 39.2 K to 41.1 K (+4.96 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 109.14 | 3,594 | 392,249 | 14,375 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 164.71 | 100 | 16,471 | 52,524 | 52.6 K to 52.5 K (-0.19 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 164.12 | 900 | 147,708 | 52,624 | 53.5 K to 52.6 K (-1.68 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 162.94 | 400 | 65,176 | 53,524 | 53.9 K to 53.5 K (-0.74 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 161.51 | 500 | 80,755 | 53,924 | 54.4 K to 53.9 K (-0.92 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 160.50 | 500 | 80,250 | 54,424 | 54.9 K to 54.4 K (-0.91 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 159.62 | 700 | 111,734 | 54,924 | 55.6 K to 54.9 K (-1.26 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 158.32 | 494 | 78,210 | 55,624 | 56.1 K to 55.6 K (-0.88 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 109.14 | 3,594 | 392,249 | 56,118 | 52.5 K to 56.1 K (+6.84 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 86.52 | 2,330 | 201,592 | 27,959 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 163.08 | 2,330 | 379,976 | 25,493 | 27.8 K to 25.5 K (-8.37 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 86.52 | 2,330 | 201,592 | 27,823 | 25.5 K to 27.8 K (+9.14 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 109.14 | 4,250 | 463,845 | 17,000 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 109.14 | 4,250 | 463,845 | 17,000 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 77.31 | 4,250 | 328,568 | 0 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 77.31 | 4,250 | 328,568 | 0 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 163.08 | 8,500 | 1,386,180 | 41,952 | 50.5 K to 42 K (-16.85 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 163.08 | 8,500 | 1,386,180 | 41,952 | 50.5 K to 42 K (-16.85 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 109.14 | 4,250 | 463,845 | 50,452 | 46.2 K to 50.5 K (+9.20 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 109.14 | 4,250 | 463,845 | 50,452 | 46.2 K to 50.5 K (+9.20 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 77.31 | 4,250 | 328,568 | 46,202 | 42 K to 46.2 K (+10.13 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 77.31 | 4,250 | 328,568 | 46,202 | 42 K to 46.2 K (+10.13 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 86.52 | 809 | 69,995 | 9,708 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 86.52 | 809 | 69,995 | 9,708 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 77.31 | 1,289 | 99,653 | 0 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 77.31 | 1,289 | 99,653 | 0 | |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 163.08 | 2,098 | 342,142 | 16,634 | 18.7 K to 16.6 K (-11.20 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 163.08 | 2,098 | 342,142 | 16,634 | 18.7 K to 16.6 K (-11.20 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 86.52 | 809 | 69,995 | 18,732 | 17.9 K to 18.7 K (+4.51 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 86.52 | 809 | 69,995 | 18,732 | 17.9 K to 18.7 K (+4.51 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 77.31 | 1,289 | 99,653 | 17,923 | 16.6 K to 17.9 K (+7.75 %) |
| Feb 07 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 77.31 | 1,289 | 99,653 | 17,923 | 16.6 K to 17.9 K (+7.75 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 91.05 | 1,796 | 163,526 | 14,368 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 91.05 | 1,796 | 163,526 | 14,368 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 169.49 | 100 | 16,949 | 49,761 | 49.9 K to 49.8 K (-0.20 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 169.49 | 100 | 16,949 | 49,761 | 49.9 K to 49.8 K (-0.20 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 167.81 | 100 | 16,781 | 49,861 | 50 K to 49.9 K (-0.20 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 167.81 | 100 | 16,781 | 49,861 | 50 K to 49.9 K (-0.20 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 166.12 | 996 | 165,456 | 49,961 | 51 K to 50 K (-1.95 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 166.12 | 996 | 165,456 | 49,961 | 51 K to 50 K (-1.95 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 165.24 | 600 | 99,144 | 50,957 | 51.6 K to 51 K (-1.16 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 165.24 | 600 | 99,144 | 50,957 | 51.6 K to 51 K (-1.16 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 91.05 | 1,796 | 163,526 | 51,557 | 49.8 K to 51.6 K (+3.61 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 91.05 | 1,796 | 163,526 | 51,557 | 49.8 K to 51.6 K (+3.61 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 91.05 | 1,796 | 163,526 | 14,368 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 91.05 | 1,796 | 163,526 | 14,368 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 169.49 | 100 | 16,949 | 52,524 | 52.6 K to 52.5 K (-0.19 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 169.49 | 100 | 16,949 | 52,524 | 52.6 K to 52.5 K (-0.19 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 168.06 | 100 | 16,806 | 52,624 | 52.7 K to 52.6 K (-0.19 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 168.06 | 100 | 16,806 | 52,624 | 52.7 K to 52.6 K (-0.19 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 166.10 | 996 | 165,436 | 52,724 | 53.7 K to 52.7 K (-1.85 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 166.10 | 996 | 165,436 | 52,724 | 53.7 K to 52.7 K (-1.85 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 165.23 | 600 | 99,138 | 53,720 | 54.3 K to 53.7 K (-1.10 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 165.23 | 600 | 99,138 | 53,720 | 54.3 K to 53.7 K (-1.10 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 91.05 | 1,796 | 163,526 | 54,320 | 52.5 K to 54.3 K (+3.42 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 91.05 | 1,796 | 163,526 | 54,320 | 52.5 K to 54.3 K (+3.42 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 167.44 | 1,900 | 318,136 | 52,524 | 54.4 K to 52.5 K (-3.49 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 167.44 | 1,900 | 318,136 | 52,524 | 54.4 K to 52.5 K (-3.49 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 91.05 | 1,289 | 117,363 | 10,313 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 96.87 | 8,594 | 832,501 | 1,719 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 91.05 | 1,289 | 117,363 | 10,313 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 169.42 | 1,289 | 218,382 | 16,634 | 17.9 K to 16.6 K (-7.19 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 96.87 | 8,594 | 832,501 | 1,719 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 91.05 | 1,289 | 117,363 | 17,923 | 16.6 K to 17.9 K (+7.75 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 169.42 | 1,289 | 218,382 | 16,634 | 17.9 K to 16.6 K (-7.19 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 174.11 | 8,594 | 1,496,301 | 16,634 | 25.2 K to 16.6 K (-34.07 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 91.05 | 1,289 | 117,363 | 17,923 | 16.6 K to 17.9 K (+7.75 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 96.87 | 8,594 | 832,501 | 25,228 | 16.6 K to 25.2 K (+51.67 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 174.11 | 8,594 | 1,496,301 | 16,634 | 25.2 K to 16.6 K (-34.07 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 96.87 | 8,594 | 832,501 | 25,228 | 16.6 K to 25.2 K (+51.67 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 174.11 | 3,450 | 600,680 | 25,493 | 28.9 K to 25.5 K (-11.92 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 2,156 | 196,304 | 17,241 | |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 169.42 | 2,156 | 365,270 | 41,952 | 44.1 K to 42 K (-4.89 %) |
| Feb 05 2018 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 91.05 | 2,156 | 196,304 | 44,108 | 42 K to 44.1 K (+5.14 %) |